Reason Magazine Rebuts Rising Calls to Limit Cannabis Potency

The Potency Argument Under Fire

Reason's editorial dismisses the premise that stronger cannabis products require government intervention, comparing potency limits to hypothetical alcohol-by-volume caps. The magazine's position aligns with industry operators who say consumer choice and proper labeling address safety concerns more effectively than statutory ceilings.

The timing is sharp. Colorado regulators are reviewing a petition to cap concentrates at 35% THC, while Minnesota's Cannabis Management Office considers similar guardrails for its adult-use rollout. Vermont lawmakers debated a 60% concentrate cap in June—then tabled it.

Where the Debate Stands in 2026

At least six state legislatures have entertained potency restrictions this year, though none have passed binding limits. The proposals range from tiered taxation (Washington's HB 1453) to mandatory health warnings on products above 25% THC (New York's pending OCM rule).

Public-health researchers cite emergency-room data showing higher rates of cannabis hyperemesis syndrome and acute psychosis among concentrate users. Industry groups counter that per-use consumption drops when potency rises. Users titrate to effect, not to a fixed dose.

The core tension: whether high-potency products represent a market innovation or a public-health red flag that demands state intervention.

For the full evolution of this policy fight, see the CannIntel topic hub on the cannabis potency debate.

Operator Pushback and Market Realities

Multi-state operators have spent the summer lobbying against potency caps, arguing they'd erase product categories that account for 30-40% of dispensary revenue. Concentrates, vapes, and infused pre-rolls routinely test above proposed thresholds.

Michigan-based Green Peak Innovations told the state's Marijuana Regulatory Agency in July that a 35% cap would eliminate live resin, rosin, and distillate cartridges. California's Bureau of Cannabis Control received similar comments from 18 licensed manufacturers during its June listening session.

The economic stakes are real:

• Concentrates represented $1.8 billion in U.S. sales in 2025, per BDSA tracking data.
• Vape cartridges—often 70-90% THC—made up 28% of Colorado's $1.3 billion adult-use market last year.
• Edibles above 10mg per piece (effectively high-potency by dose) drove 19% of Illinois revenue in Q1 2026.

What Comes Next

The potency debate will likely shift from op-ed pages to administrative rulemaking by year-end. Colorado's Marijuana Enforcement Division has until October 15 to issue findings on the concentrate petition. Minnesota's draft adult-use rules, due in September, are expected to include potency language.

Washington State's tiered-tax bill remains in committee. Its sponsor—Rep. Tana Senn—has signaled she'll reintroduce it in the 2027 session with tighter potency brackets. New York's Office of Cannabis Management hasn't set a timeline for finalizing its warning-label proposal.

Industry observers expect the fight to pivot toward labeling and education mandates rather than outright caps. That's the path Vermont took after its cap bill stalled.